Accès ouvert déclaré
2023
article
Lack of impact of ipragliflozin on endothelial function in patients with type 2 diabetes: sub-analysis of the PROTECT study
Shinji Kishimoto, Yukihito Higashi, Takumi Imai, Kazuo Fukumoto, Hirofumi Tomiyama, Koji Maemura, Atsushi Tanaka, Koichi Node, Toyoaki Murohara, Masafumi Kitakaze, Yoshihiko Nishio, Teruo Inoue, Mitsuru Ohishi, Kazuomi Kario, Masataka Sata, Michio Shimabukuro, Wataru Shimizu, Hideaki Jinnouchi, Isao Taguchi, Makoto Suzuki, Shin‐ichi Ando, Haruo Kamiya, Tomohiro Sakamoto, Hiroki Teragawa, Mamoru Nanasato, Munehide Matsuhisa, Junya Ako, Yoshimasa Aso, Masaharu Ishihara, Kazuo Kitagawa, Akira Yamashina, Tomoko Ishizu, Yumi Ikehara, Shinichiro Ueda, Ayako Takamori, Hisako Yoshida, Miki Mori, Kaori Yamaguchi, Machiko Asaka, Tetsuya Kaneko, Masashi Sakuma, Shigeru Toyoda, Takahisa Nasuno, Michiya Kageyama, Toshie Iijima, Haruka Kishi, Hirotsugu Yamada, Kenya Kusunose, Daiju Fukuda, Shusuke Yagi, Koji Yamaguchi, Takayuki Ise, Yutaka Kawabata, Akio Kuroda, Yuichi Akasaki, Mihoko Kurano, Satoshi Hoshide, Takahiro Komori, Tomoyuki Kabutoya, Yukiyo Ogata, Yuji Koide, Hiroaki Kawano, Satoshi Ikeda, Satoki Fukae, Seiji Koga, Masato Kajikawa, Tatsuya Maruhashi, Yoshiaki Kubota, Yoshisato Shibata, Nehiro Kuriyama, Ikuko Nakamura, Kanemitsu Hironori, Bonpei Takase, Yuichi Orita, Chikage Oshita, Yuko Uchimura, Ruka Yoshida, Yukihiko Yoshida, Hirohiko Suzuki, Yasuhiro Ogura, Mayuho Maeda, Masaki Takenaka, Takumi Hayashi, Mirai Hirose, Itaru Hisauchi, Toshiaki Kadokami, Ryô Nakamura, Junji Kanda, Kazuo Matsunaga, Masaaki Hoshiga, Koichi Sohmiya, Yumiko Kanzaki, Arihiro Koyosue, Hiroki Uehara, Naoto Miyagi, Toshiya Chinen, Kentaro Nakamura, Chikashi Nago, Suguru Chiba, Sho Hatano, Yoshikatsu Gima, Masami Abe, Masayoshi Ajioka, Hiroshi Asano, Yoshihiro Nakashima, Hiroyuki Osanai, Takahiro Kanbara, Yusuke Sakamoto, Mitsutoshi Oguri, Shiou Ohguchi, Kunihiko Takahara, Kazuhiro Izumi, Kenichiro Yasuda, Akihiro Kudo, Noritaka Machii, Ryota Morimoto, Yoshiyuki Bando, Takahiro Okumura, Toru Kondo, Shin‐ichiro Miura, Yuhei Shiga, Joji Mirii, Makoto Sugihara, Tadaaki Arimura, Junko Nakano, Kazuhisa Kodama, Nobuyuki Ohte, Tomonori Sugiura, Kazuaki Wakami, Yasuhiko Takemoto, Minoru Yoshiyama, Taichi Shuto, Yosuke Okada, Kenichi Tanaka, Satomi Sonoda, Akemi Tokutsu, Takashi Otsuka, Fumi Uemura, Kenji Koikawa, Megumi Miyazaki, Maiko Umikawa, Manabu Narisawa, Machi Furuta, Hiroshi Minami, M. Doi, Kazuhiro Sugimoto, Susumu Suzuki, Akira Kurozumi, Kosuke Nishio
7Citations signalées, ce qui n’est pas une note de qualité
7Institutions déclarées
1Pays d’affiliation déclarés
Rattachement africain : jp.
Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
BACKGROUND: We assessed the impact of 24 months of treatment with ipragliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, on endothelial function in patients with type 2 diabetes as a sub-analysis of the PROTECT study. METHODS: In the PROTECT study, patients were randomized to receive either standard antihyperglycemic treatment (control group, n = 241 ) or add-on ipragliflozin treatment (ipragliflozin group, n = 241) in a 1:1 ratio. Among the 482 patients in the PROTECT study, flow-mediated vasodilation (FMD) was assessed in 32 patients in the control group and 26 patients in the ipragliflozin group before and after 24 months of treatment. RESULTS: HbA1c levels significantly decreased after 24 months of treatment compared to the baseline value in the ipragliflozin group, but not in the control group. However, there was no significant difference between the changes in HbA1c levels in the two groups (7.4 ± 0.8% vs. 7.0 ± 0.9% in the ipragliflozin group and 7.4 ± 0.7% vs. 7.3 ± 0.7% in the control group; P = 0.08). There was no significant difference between FMD values at baseline and after 24 months in both groups (5.2 ± 2.6% vs. 5.2 ± 2.6%, P = 0.98 in the ipragliflozin group; 5.4 ± 2.9% vs. 5.0 ± 3.2%, P = 0.34 in the control group). There was no significant difference in the estimated percentage change in FMD between the two groups (P = 0.77). CONCLUSIONS: Over a 24-month period, the addition of ipragliflozin to standard therapy in patients with type 2 diabetes did not change endothelial function assessed by FMD in the brachial artery. TRIAL REGISTRATION: Registration Number for Clinical Trial: jRCT1071220089 ( https://jrct.niph.go.jp/en-latest-detail/jRCT1071220089 ).
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Lack of impact of ipragliflozin on endothelial function in patients with type 2 diabetes: sub-analysis of the PROTECT study
- Date Crossref
- 20/05/2023
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Les institutions déclarées
Une affiliation ne permet pas de déduire la nationalité d’un auteur.
Les sujets associés
Diabetes Treatment and ManagementHyperglycemia and glycemic control in critically ill and hospitalized patientsCardiovascular Health and Disease Prevention